Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )

Canan Kas

Status: Completed

Conditions: Cancer

Treatments: Behavioral: Sexual Coercion

Study type: Interventional

Funder types: Other

Identifiers

NCT06840847

2023-KAEK-148

Kastamonu Universty 2023/148 (Other Grant/Funding Number)

Details and patient eligibility

About

The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

Full description

Objective: The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

Methods: This study is a randomized controlled study. In this study, the validated Turkish version of the Sexual Coercion in Intimate Relationship Scale was utilized to investigate whether patients receiving LHRHa therapy experienced higher rates of sexual sexual coercion compared to those taking tamoxifen. The study included 40 patients using LHRHa and 39 patients using tamoxifen. The instrument assessed partner sexual coercion across three subdomains: resource manipulation/sexual coercion, commitment manipulation, and defection threat.

Enrollment: 79 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• being over 18 years of age
• willingness to participate in this study
• having received treatment for breast cancer
• having a history of breast cancer surgery
• having an active relationship with a spouse or partner.

Exclusion criteria

• having any neuropsychiatric disorder
• having any mental illness
• having a history of gynecological surgery
• currently receiving active chemotherapy or less than 3 months since completing chemotherapy
• receiving treatment for metastatic disease
• The use of selective serotonin reuptake inhibitors

Trial design

Primary purpose: Health Services Research

Allocation: Non-Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)

---

79 participants in 2 patient groups

LHRHa

Active Comparator group

Description:

In this study, included 40 patients on LHRHa. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Treatment:

Behavioral: Sexual Coercion

Tamoxifen (Nolvadex)

Active Comparator group

Description:

In this study included 39 patients on tamoxifen. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Treatment:

Behavioral: Sexual Coercion